The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice

Autor: T.I. Ionova, A.A. Amdiev, M.I. Andrievskikh, E.A. Baryakh, E.V. Vasil’ev, M.V. Volkov, E.M. Volodicheva, V.V. Ivanov, O.V. Kaverina, K.D. Kaplanov, T.Yu. Klitochenko, V.I. Kurakin, D.G. Lazareva, O.G. Larionova, K.V. Lepik, I.B. Lysenko, V.Ya. Melnichenko, R.I. Minullina, O.V. Mironov, E.N. Misyurina, N.B. Mikhailova, N.E. Mochkin, Tatyana Pavlovna Nikitina, T.S. Petrova, N.M. Porfirieva, O.A. Rukavitsyn, A.A. Samoilova, R.N. Safin, P.I. Simashova, E.G. Smirnova, N.A. Trenina, N.V. Fadeeva, G.N. Khusainova, V.L. Chang, T.V. Shelekhova, D.G. Sherstnev
Rok vydání: 2022
Předmět:
Zdroj: Clinical oncohematology. 15:42-53
ISSN: 2500-2139
1997-6933
DOI: 10.21320/2500-2139-2022-15-1-42-53
Popis: Aim. To study the quality of life and symptoms, to assess the clinical effect and treatment safety in relapsed/refractory classical Hodgkin’s lymphoma (r/r cHL) patients treated with brentuximab vedotin (BV) as > 3rd-line therapy in the context of real clinical practice. Materials & Methods. The study enrolled 62 r/r cHL patients after the second- and subsequent-line chemotherapies, who are either ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) at the time of their enrollment into the study or after the failure of high-dose chemotherapy (HDCT) with auto-HSCT. The median age was 31 years; 46.8 % of patients were women. The patients received BV 1.8 mg/kg intravenously every 3 weeks. Clinical parameters, quality of life, and symptoms were assessed prior to BV therapy and in 3, 6, 9, 12, and 15 months after therapy onset. The RAND SF-36 form was used to assess the quality of life, and the ESAS-R tool was applied to report on symptoms. Results. Objective response was observed in 68.3 % of patients, 40 % out of them showed complete response. The median progression-free survival was 10.6 months (95% confidence interval 7.4-12.9 months). Safety profile corresponded to the published data. Adverse events of grade 3/4 were identified in 1.6 % of patients. In the period of 15 months after therapy onset, quality of life improvement or stabilization was reported based on all the scales of RAND SF-36 (GEE, p < 0.001), and symptom relief was shown based on ESAS-R total score (GEE, p < 0.001). Conclusion. In the context of real clinical practice, BV appeared to be effective in r/r cHL patients either after the second- or subsequent-line chemotherapies or after the failure of HDCT with auto-HSCT. The study demonstrated that BV was well tolerated by the patients. BV therapy contributes to the improvement of r/r cHL patients’ quality of life. Positive changes in quality of life and symptoms on BV therapy testify to its patient-assessed efficacy and safety.
Databáze: OpenAIRE
Externí odkaz: